This photo provided by Eli Lilly shows the drug bamlanivimab. On Tuesday, Jan. 26, 2021, the company said that the two-antibody combo of bamlanivimab and etesevimab reduced the risk of hospitalizations or death by 70% in newly diagnosed, non-hospitalized COVID-19 patients at high risk of serious illness because of age or other health conditions. (Eli Lilly via AP)
Southern California wildfire destroys 132 structures as officials look for fierce winds to subside Shares
Ovechkin scoring another game-winning goal for the Capitals comes as no surprise to the Predators Shares
4 astronauts return to Earth after being delayed by Boeing's capsule trouble and Hurricane Milton Shares